16 results match your criteria: "From Brigham and Women's Hospital and Harvard Medical School - both in Boston.[Affiliation]"

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.

N Engl J Med

January 2022

From Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.), and Care United Research, Forney (S.M.) - all in Texas; the Nuren Medical and Research Center, Miami (C.E.V.), Evolution Clinical Trials, Hialeah Gardens (G.P.), the Midland Florida Clinical Researc

Background: Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is uncertain.

Methods: We conducted a randomized, double-blind, placebo-controlled trial involving nonhospitalized patients with Covid-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression (age ≥60 years, obesity, or certain coexisting medical conditions).

View Article and Find Full Text PDF

Women's Health - Traversing Medicine and Public Policy.

N Engl J Med

June 2021

From the Department of Medicine, University of California, San Diego, School of Medicine, La Jolla (C.A.S.); and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School - both in Boston (J.E.M.).

View Article and Find Full Text PDF

Misdiagnosis, Mistreatment, and Harm - When Medical Care Ignores Social Forces.

N Engl J Med

March 2020

From the University of California Berkeley, Berkeley, and the University of California San Francisco, San Francisco (S.M.H.); New York University, New York (H.H.); the University of California Irvine, Irvine (A.J.); the University of Michigan, Ann Arbor (S.D.S.); Brigham and Women's Hospital and Har

View Article and Find Full Text PDF